Physician profile
Robert T Ching
NPI 1770565707
$19,500.38
in general payments reported to CMS, 2019-2025
63 companies · $2,794 in 2025
The $2,794 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,556 · 2020: $2,290 · 2021: $2,740 · 2022: $2,666 · 2023: $3,679 · 2024: $2,776 · 2025: $2,794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,009 · Education: $240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,008.75 |
| Education | $240.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,599.07 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $2,041.77 | 2020-2025 | Vraylar, Ubrelvy, Linzess |
| Lilly USA, LLC | $1,600.00 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $1,530.24 | 2019-2025 | Otezla, Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $1,400.58 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,222.10 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $841.17 | 2019-2024 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $667.20 | 2019-2025 | Belsomra, Gardasil 9, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $660.97 | 2021-2025 | |
| Pfizer INC. | $623.14 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $536.01 | 2019-2025 | Xifaxan |
| Allergan, INC. | $425.46 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $423.97 | 2019-2025 | |
| Amarin Pharma, INC. | $357.46 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $304.91 | 2019-2023 | Xarelto, Spravato |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ching listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.